Blood-aqueous Barrier Integrity in Eyes Undergoing Intravitreal Bevacizumab Therapy to Treat Neovascular AMD

Medical University of Lublin

Status: Completed

Conditions: Exudative Age-related Macular Degeneration

Treatments: Drug: Bevacizumab Injection

Study type: Observational

Funder types: Other

Identifiers

NCT03744806

KE-0254/208/2013

Details and patient eligibility

About

The aim of this study is to evaluate the effect of repeated intravitreal bevacizumab injections on blood-aqueous barrier permeability in eyes with neovascular age-related macular degeneration (AMD).

Enrollment: 48 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• active AMD-associated choroidal neovascularization (CNV) confirmed with fluorescein angiography (FA) and optical coherence tomography (OCT)

Exclusion criteria

• history of uveitis, vitreous hemorrhage, neovascular glaucoma, corneal opacities, recent ocular surgery (within 3 months), or prior anti- vascular endothelial growth factor (VEGF) injections

Trial design

48 participants in 2 patient groups

treated with intravitreal bevacizumab.

Treatment:

Drug: Bevacizumab Injection

control group